Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company focused on developing innovative therapies for life-threatening diseases. This page provides investors and healthcare professionals with timely updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of Gilead's press releases and news, including updates on antiviral therapies, oncology research, and clinical trial results. Our curated collection features earnings announcements, partnership details, and progress reports on treatments for HIV, hepatitis, and emerging cancer therapies.
Stay informed about critical developments through verified updates on FDA approvals, research collaborations, and therapeutic advancements. All content is organized chronologically for quick reference, with clear sourcing to ensure transparency.
Bookmark this page for streamlined access to Gilead Sciences' official communications and third-party analysis. Regularly updated to reflect the company's evolving pipeline and market position, this resource supports informed decision-making for stakeholders at all levels.
Arcellx and Kite, in partnership with Gilead Company, announced updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program. The global Phase 3 trial, iMMagine-3, will evaluate anito-cel in patients with relapsed and/or refractory multiple myeloma exposed to specific previous treatments. The technical transfer for manufacturing anito-cel is complete, and preliminary data from the iMMagine-1 trial is expected by year-end.
Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.
Gilead's FOCUS Program, launched in 2010, has been instrumental in early HIV detection and linkage to care. By partnering with state and local officials, healthcare providers, and organizations, the program has significantly reduced late-stage HIV diagnoses in underserved populations across the United States.
Gilead's partnership with the government of Mauritius has helped in the elimination of Hepatitis C in the country. By providing low-cost treatment and working with high-prevalence regions, the company has contributed to the success of patients like James, who is now free from the disease. The government's commitment and public-private partnerships have been instrumental in the progress towards eradicating Hepatitis C in the region.
Gilead Sciences, Inc. and Kite, a Gilead Company, will present 18 abstracts at the 2024 ASCO Annual Meeting, showcasing their commitment to developing innovative cancer treatments. The data cover a broad range of cancers, including lung, breast, and gastrointestinal, with highlights on Trodelvy in NSCLC, gastrointestinal pipeline progress, and new CAR T-cell therapy data. The company continues to focus on transforming cancer treatment through groundbreaking research.
Forbes has recognized Gilead as one of America's Best Employers for Diversity. The company's commitment to inclusion and diversity is highlighted, reflecting positive feedback from employees and the community. Gilead Sciences, a biopharmaceutical company, aims to innovate medicines for unmet medical needs globally.
Gilead Sciences, Inc. (Nasdaq: GILD) executives will be speaking at several upcoming investor conferences, showcasing the company's commitment to advancing innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The live webcasts and replays will be available on the company's investors page. Gilead operates globally with headquarters in Foster City, California.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
